Trial
NCT05125562
Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19
Phase IIWITHDRAWNREGULATORYConfidence: HIGH
Sponsor
Direct Biologics, LLC
Collaborators
—
Condition
COVID-19
Intervention
ExoFlo
Why stopped
Sponsor has withdrawn/closed the IND with the FDA. A letter dated 21NOV2022 was submitted to the FDA.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-02-13